Effect of salt and temperature stresses on survival and infectivity of Heterorhabditis spp. IJs

Heterorhabditis is frequently found in coastal sandy soils where it may experience both high salinity and high temperatures. We tested the ability of infective juveniles (IJs) of three taxonomic groups of Heterorhabditis to infect insects in saline sand. We also tested whether salinity (sea water) affected the IJs' ability to tolerate elevated temperatures in aqueous suspension and in sand. IJs of all three taxonomic groups killed Galleria mellonella in saline sand (25.6% insects killed), but at a lower level than in non-saline sand (96.5% insects killed). Exposure of IJs in sand to high temperature reduced their ability to kill G. mellonella at 20 degrees C; heating IJs in saline sand reduced G. mellonella mortality to a lesser extent (25.6% at 20 degrees C, 18.3% at 39 degrees C) than heating in non-saline sand (96.5% at 20 degrees C, 17.5% at 39 degrees C). In aqueous suspension, IJs of the North-West European and Irish types of Heterorhabditis tolerated high temperature better in sea water (at least 95% survived 1 h at 39 C) than in distilled water (none survived 1 h at 38 degrees C). H. bacteriophora was more temperature tolerant: survival and subsequent infectivity of IJs was unaffected by temperature up to 39 degrees C in either medium. It was concluded that high salinity (sea water) reduces the ability of Heterorhabditis IJs to infect, but improves their tolerance of high temperature

Effect of salt and temperature stresses on survival and infectivity of Heterorhabditis spp. IJs

Heterorhabditis is frequently found in coastal sandy soils where it may experience both high salinity and high temperatures. We tested the ability of infective juveniles (IJs) of three taxonomic groups of Heterorhabditis to infect insects in saline sand. We also tested whether salinity (sea water) affected the IJs' ability to tolerate elevated temperatures in aqueous suspension and in sand. IJs of all three taxonomic groups killed Galleria mellonella in saline sand (25.6% insects killed), but at a lower level than in non-saline sand (96.5% insects killed). Exposure of IJs in sand to high temperature reduced their ability to kill G. mellonella at 20 degrees C; heating IJs in saline sand reduced G. mellonella mortality to a lesser extent (25.6% at 20 degrees C, 18.3% at 39 degrees C) than heating in non-saline sand (96.5% at 20 degrees C, 17.5% at 39 degrees C). In aqueous suspension, IJs of the North-West European and Irish types of Heterorhabditis tolerated high temperature better in sea water (at least 95% survived 1 h at 39 C) than in distilled water (none survived 1 h at 38 degrees C). H. bacteriophora was more temperature tolerant: survival and subsequent infectivity of IJs was unaffected by temperature up to 39 degrees C in either medium. It was concluded that high salinity (sea water) reduces the ability of Heterorhabditis IJs to infect, but improves their tolerance of high temperature

Knowledge translation and the power of the nursing academic conference

The national and international conference experiences present a unique learning opportunity. There are differing events that reflect the full nursing employment spectrum from clinical delivery, organizational and policy development and academia in education and research. Many conferences provide a platform for academics with differing levels of experience to come together and welcome contributions from students and all grades of post-registration nurses, educationalists, administrators, and researchers. In selecting the programme, the conference organisers will often circulate a calling notice and potential presenters will submit their abstracts to be blind peer reviewed. Therefore, conferences showcase the best of the best and provide the current perspective of areas of growth within the nursing sector. Conferences have a plethora of delivery routes ranging from posters, oral presentations (both short and long), panel discussions, key notes, seminars, exhibitions and workshops. These present an exceptional chance to listen, present, network and discuss nursing innovation and academic research

Where We Fall Down: Tensions in Teaching Social Medicine and Global Health

Background: As global health interest has risen, so too has the relevance of education on the social determinants of health and health equity. Social medicine offers a particularly salient framework for educating on the social determinants of health, health disparities, and health equity. SocMed and EqualHealth, 2 unique but related organizations, offer annual global health courses in Uganda, Haiti, and the United States, which train students to understand and respond to the social determinants of health through praxis, self-reflection and self-awareness, and building collaborative partnerships across difference. Objectives: The aim of this paper is to describe an innovative pedagogical approach to teaching social medicine 'and' global health. We draw on the notion of praxis, which illuminates the value of iterative reflection and action, to critically examine our points of weakness as educators in order to derive lessons with broad applicability for those engaged in global health work. Methods: The data for this paper were collected through an autoethnography of teaching 10 global health social medicine courses in Uganda and Haiti since 2010. It draws on revealing descriptions from participant observation, student feedback collected in anonymous course evaluations, and ongoing relationships with alumni. Findings: Critical analysis reveals 3 significant and complicated tensions raised by our courses. The first point of weakness pertains to issues of course ownership by North American outsiders. The second tension emerges from explicit acknowledgment of social and economic inequities among our students and faculty. Finally, there are ongoing challenges of sustaining positive momentum toward social change after transformative course experiences. Conclusions: Although successful in generating transformative learning experiences, these courses expose significant fracture points worth interrogating as educators, activists, and global health practitioners. Ultimately, we have identified a need for building equitable partnerships and intentional community, embracing discomfort, and moving beyond reflection to praxis in global health education

Specific Adherence of Sporangia of a Paenibacillus Sp. Bacterium to Heterorhabditis Spp. Nematodes. Hitching a Ride to Lunch?

The fact that entomopathogenic nematodes of the genera Heterorhabditis and Stemernema are normally found in mutuahstic association with the bacteria Photorhabdus spp. and Xenorhabdus spp , respectively, has long been universally accepted However, the extent and nature of their interaction with bacteria other than these, under natural conditions, is less well known. There have been a number of reports of other bacteria being isolated from entomopathogenic nematodes, particularly from Stemernema spp. (reviewed by Boemare et al, 1998a). Jackson et al (1995) reported the occurrence oí Providencia rettgeri with a number of strains of Heterorhabditis spp. originating from different geographical regions. Boemare et al (1998b) point out that écologiste will tend to harvest nematodes resulting from "successful" parasitisms, i e. those where the cadaver is not more rapidly putrefied by the presence of co-associated bacteria other that the natural symbiont. With this in mind it is conceivable that we may under-estimate the frequency of association of these nematodes with other bacteria

Long-Term Safety Evaluation of Ubrogepant for the Acute Treatment of Migraine: Phase 3, Randomized, 52-Week Extension Trial.

OBJECTIVE: To evaluate the long-term safety and tolerability of ubrogepant for the acute treatment of migraine. BACKGROUND: Ubrogepant is an oral, calcitonin gene-related receptor antagonist in development for the acute treatment of migraine. The efficacy of ubrogepant was demonstrated in 2 phase 3 trials in which a significant improvement was observed in migraine headache pain, migraine-associated symptoms, and ability to function. METHODS: This was a phase 3, multicenter, randomized, open-label, 52-week extension trial. Adults with migraine with or without aura entered the trial after completing one of 2 phase 3 lead-in trials and were re-randomized 1:1:1 to usual care, ubrogepant 50 mg, or ubrogepant 100 mg. Randomization to ubrogepant dose was blinded. Those randomized to usual care continued to treat migraine attacks with their own medication. The usual care arm was included in this trial to capture background rates of hepatic laboratory parameters and contextualize hepatic safety assessments. Safety and tolerability were the primary outcome measures. The safety population for the ubrogepant arms included all randomized participants who received at least 1 dose of treatment. All cases of alanine aminotransferase (ALT)/aspartate aminotransferase (AST) elevations of ≥3 times the upper limit of normal were adjudicated by an independent panel of liver experts who were blinded to dose. RESULTS: The safety population included 1230 participants (404 in the ubrogepant 50-mg group, 409 in the ubrogepant 100-mg group, and 417 in the usual care group). Participants were on average 42 years of age, 90% (1106/1230) female and 85% (1043/1230) white, with an average BMI of 30 kg/m CONCLUSIONS: Long-term intermittent use of ubrogepant 50 and 100 mg given as 1 or 2 doses per attack for the acute treatment of migraine was safe and well tolerated, as indicated by a low incidence of treatment-related TEAEs and SAEs and discontinuations due to adverse events in this 1-year trial

Safety and Tolerability Results of Atogepant for the Preventive Treatment of Episodic Migraine From a 40-Week, Open-Label Multicenter Extension of the Phase 3 ADVANCE Trial

Background: Atogepant is a United States Food and Drug Administration-approved oral calcitonin gene-related peptide receptor antagonist for the preventive treatment of episodic migraine. The study objective was to evaluate the long-term safety and tolerability of atogepant in participants who completed the phase 3 ADVANCE trial (NCT03777059). Methods: This 40-week, open-label extension trial (NCT03939312) monitored safety in participants receiving oral atogepant 60 mg once daily, followed by a four-week safety follow-up period. Results: Of the 685 participants taking at least one dose of atogepant, the treatment period was completed by 74.6% of participants with a mean (standard deviation) treatment duration of 233.6 (89.3) days. Treatment-emergent adverse events occurred in 62.5% of participants, with upper respiratory tract infection (5.5%), urinary tract infection (5.3%), nasopharyngitis (4.8%), sinusitis (3.6%), constipation (3.4%), and nausea (3.4%) occurring at ≥3%. Serious adverse events were observed in 3.4% of participants (none were treatment-related), and there were no deaths. Adverse events leading to discontinuation occurring at \u3e0.1% were nausea (0.4%) and abdominal pain, vomiting, weight decrease, dizziness, and migraine (0.3% each). Conclusion: These results are consistent with atogepant\u27s known safety profile and support long-term use of atogepant 60 mg once daily dosing as safe and well tolerated.ClinicalTrials.gov Registration Number: NCT03939312

Specificity of the STAT4 Genetic Association for Severe Disease Manifestations of Systemic Lupus Erythematosus

Systemic lupus erythematosus (SLE) is a genetically complex disease with heterogeneous clinical manifestations. A polymorphism in the STAT4 gene has recently been established as a risk factor for SLE, but the relationship with specific SLE subphenotypes has not been studied. We studied 137 SNPs in the STAT4 region genotyped in 4 independent SLE case series (total n = 1398) and 2560 healthy controls, along with clinical data for the cases. Using conditional testing, we confirmed the most significant STAT4 haplotype for SLE risk. We then studied a SNP marking this haplotype for association with specific SLE subphenotypes, including autoantibody production, nephritis, arthritis, mucocutaneous manifestations, and age at diagnosis. To prevent possible type-I errors from population stratification, we reanalyzed the data using a subset of subjects determined to be most homogeneous based on principal components analysis of genome-wide data. We confirmed that four SNPs in very high LD (r2 = 0.94 to 0.99) were most strongly associated with SLE, and there was no compelling evidence for additional SLE risk loci in the STAT4 region. SNP rs7574865 marking this haplotype had a minor allele frequency (MAF) = 31.1% in SLE cases compared with 22.5% in controls (OR = 1.56, p = 10−16). This SNP was more strongly associated with SLE characterized by double-stranded DNA autoantibodies (MAF = 35.1%, OR = 1.86, p<10−19), nephritis (MAF = 34.3%, OR = 1.80, p<10−11), and age at diagnosis<30 years (MAF = 33.8%, OR = 1.77, p<10−13). An association with severe nephritis was even more striking (MAF = 39.2%, OR = 2.35, p<10−4 in the homogeneous subset of subjects). In contrast, STAT4 was less strongly associated with oral ulcers, a manifestation associated with milder disease. We conclude that this common polymorphism of STAT4 contributes to the phenotypic heterogeneity of SLE, predisposing specifically to more severe disease

Fish oil administration in older adults: is there potential for adverse events? A systematic review of the literature

ackground: Omega-3 (n-3) fatty acid supplementation is becoming increasingly popular. However given its antithrombotic properties the potential for severe adverse events (SAE) such as bleeding has safety implications, particularly in an older adult population. A systematic review of randomized control trials (RCT) was conducted to explore the potential for SAE and non-severe adverse events (non-SAE) associated with n-3 supplementation in older adults. Methods: A comprehensive search strategy using Medline and a variety of other electronic sources was conducted. Studies investigating the oral administration of n-3 fish oil containing eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) or both against a placebo were sourced. The primary outcome of interest included reported SAE associated with n-3 supplementation. Chi-square analyses were conducted on the pooled aggregate of AEs. Results: Of the 398 citations initially retrieved, a total of 10 studies involving 994 older adults aged ≥60 years were included in the review. Daily fish oil doses ranged from 0.03 g to 1.86 g EPA and/or DHA with study durations ranging from 6 to 52 weeks. No SAE were reported and there were no significant differences in the total AE rate between groups (n-3 intervention group: 53/540; 9.8%; placebo group: 28/454; 6.2%; p= 0.07). Non-SAE relating to gastrointestinal (GI) disturbances were the most commonly reported however there was no significant increase in the proportion of GI disturbances reported in participants randomized to the n-3 intervention (n-3 intervention group: 42/540 (7.8%); placebo group: 24/454 (5.3%); p= 0.18). Conclusions: The potential for AEs appear mild-moderate at worst and are unlikely to be of clinical significance. The use of n-3 fatty acids and the potential for SAE should however be further researched to investigate whether this evidence is consistent at higher doses and in other populations. These results also highlight that well-documented data outlining the potential for SAE following n-3 supplementation are limited nor adequately reported to draw definitive conclusions concerning the safety associated with n-3 supplementation. A more rigorous and systematic approach for monitoring and recording AE data in clinical settings that involve n-3 supplementation is required.The authors would like to acknowledge funding provided for the ongoing ATLANTIC randomized controlled trial supported by the National Health and Medical Research Council (NHMRC), Australia

I wanted to feel the way they did: Mimesis as a situational dynamic of peer mentoring by ex-offenders

This is an Accepted Manuscript of an article published by Taylor & Francis in Deviant Behavior on 10/10/2016, available online: http://www.tandfonline.com/doi/full/10.1080/01639625.2016.1237829Despite growing enthusiasm for peer mentoring as a criminal justice intervention, very little is known about what actually happens within these relationships. Drawing on an ethnographic study of peer mentoring in the North of England this article will foreground the concept of inspiration” in these settings. It will argue that Rene Girard’s theory of mimesis offers a framework with which to analyze role modeling in mentoring relationships and that a Girardian reading also offers interesting insights into the unresolved problem of the origins of personal change